Catalent, Inc. (NYSE:CTLT) Position Raised by Cambridge Investment Research Advisors Inc.

Cambridge Investment Research Advisors Inc. raised its stake in Catalent, Inc. (NYSE:CTLT – Get Rating) by 41.2% during the fourth quarter, according to its most recent disclosure with the SEC. The fund owned 11,415 shares of the company’s stock after buying an additional 3,328 shares during the quarter. Cambridge Investment Research Advisors Inc.’s holdings in Catalent were worth $514,000 as of its most recent SEC filing.

A number of other hedge funds also recently added to or reduced their stakes in CTLT. Veritas Asset Management LLP lifted its stake in Catalent by 60.5% in the fourth quarter. Veritas Asset Management LLP now owns 11,169,815 shares of the company’s stock valued at $502,753,000 after buying an additional 4,212,040 shares during the last quarter. BlackRock Inc. increased its holdings in shares of Catalent by 5.2% during the third quarter. BlackRock Inc. now owns 16,086,469 shares of the company’s stock valued at $1,164,016,000 after purchasing an additional 792,923 shares during the period. Artisan Partners Limited Partnership increased its holdings in shares of Catalent by 12.2% during the third quarter. Artisan Partners Limited Partnership now owns 5,868,803 shares of the company’s stock valued at $424,667,000 after purchasing an additional 636,031 shares during the period. Vanguard Group Inc. increased its holdings in shares of Catalent by 2.7% during the first quarter. Vanguard Group Inc. now owns 18,971,342 shares of the company’s stock valued at $2,103,921,000 after purchasing an additional 492,071 shares during the period. Finally, New York State Common Retirement Fund increased its holdings in shares of Catalent by 62.2% during the fourth quarter. New York State Common Retirement Fund now owns 839,076 shares of the company’s stock valued at $37,767,000 after purchasing an additional 321,639 shares during the period. 99.38% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

A number of research analysts have recently commented on CTLT shares. Barclays lowered their price target on Catalent from $40.00 to $35.00 in a report on Sunday, May 21st. Deutsche Bank Aktiengesellschaft raised their price target on Catalent from $29.00 to $37.00 in a report on Monday. StockNews.com started coverage on Catalent in a report on Thursday, May 18th. They set a “sell” rating on the stock. Morgan Stanley lowered their target price on Catalent from $85.00 to $50.00 in a report on Monday. Finally, Robert W. Baird lowered their target price on Catalent from $53.00 to $35.00 in a report on Monday. Two analysts have rated the stock with a sell rating, six have given a hold rating and four have issued a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $67.55.

Catalent Trading Down 1.5 %

Shares of CTLT opened at $36.88 on Friday. The business’s 50-day moving average price is $50.54 and its 200 day moving average price is $52.80. The stock has a market capitalization of $6.64 billion, a P/E ratio of 16.32, a P/E/G ratio of 5.42 and a beta of 1.17. Catalent, Inc. has a 1-year low of $31.45 and a 1-year high of $115.33. The company has a current ratio of 1.91, a quick ratio of 1.38 and a debt-to-equity ratio of 0.86.

Insider Buying and Selling

In related news, SVP Mario Gargiulo sold 678 shares of Catalent stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the transaction, the senior vice president now owns 5,676 shares of the company’s stock, valued at approximately $283,005.36. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. In other Catalent news, insider Manja Boerman sold 1,446 shares of the firm’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total transaction of $72,097.56. Following the completion of the sale, the insider now directly owns 14,414 shares in the company, valued at approximately $718,682.04. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Mario Gargiulo sold 678 shares of the firm’s stock in a transaction dated Monday, May 1st. The stock was sold at an average price of $49.86, for a total value of $33,805.08. Following the sale, the senior vice president now owns 5,676 shares of the company’s stock, valued at $283,005.36. The disclosure for this sale can be found here. 0.58% of the stock is currently owned by company insiders.

About Catalent

(Get Rating)

Catalent, Inc is a holding company, which engages in the provision of delivery technologies, development, and manufacturing solutions for drugs, biologics, cell and gene therapies, and consumer health products. It operates through the following segments: Softgel and Oral Technologies, Biologics, Oral and Specialty Delivery, and Clinical Supply Services.